Combined effect of cytostatic drugs and E-N-L-trimethyl lysine in healthy and transplantable tumor bearing mice.
E-N-L-trimethyl lysine (TML) decreases the toxicity of Vincristin, Cyclophosphamide and Doxorubicin (Adriamycin) when administered simultaneously to healthy mice. Simultaneous treatment of L1210 ascites leukemia bearing mice with 100 mg/kg TML and 2, 2.5, 3.2, 3.5, 4 mg/kg Vincristin or 10-15; 20 mg/kg Doxorubicin increases significantly the survival of the animals when compared with untreated and Vincristin or Doxorubicin treated mice. Repeated impulse treatment of S-180 subcutaneous sarcoma with 100 mg/kg TML and 50-100 mg/kg Cyclophosphamide results in a significantly higher surviving time and surviving rate than Cyclophosphamide treatment alone.
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D008239:Lysine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D008934:Mitogens / Q000008:administration & dosage / Q000494:pharmacology*; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D014750:Vincristine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D008934:Mitogens; C003712:trimethyllysine; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D008239:Lysine